---

Related Articles:

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

2014-12-01

[Lancet Oncol. 15(13) , 1460-8, (2014)]

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

2014-08-15

[Cancer Res. 74(16) , 4446-57, (2014)]

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

2014-01-01

[J. Cancer Res. Clin. Oncol. 140(1) , 159-66, (2014)]

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

2015-04-01

[Int. J. Oncol. 46(4) , 1481-90, (2015)]

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

2014-08-15

[Am. J. Respir. Crit. Care Med. 190(4) , 456-67, (2014)]